AKBA

Akebia Therapeutics' stock price has been impacted by several events. In October 2025, the company announced it would not pursue a broad label for Vafseo for non-dialysis dependent chronic kidney disease (NDD-CKD) patients. In February 2026, AKBA shares gained 9.1% following its Q4 2025 earnings announcement. The company's Q1 2026 earnings report on May 7, 2026, led to a significant stock drop of over 20% due to a net loss of $9.1 million and lower Auryxia sales. An increase in generic competition for Auryxia is expected to further reduce its revenues in 2026. Over the past year, the share price declined by 54.51%, and as of May 7, 2026, the stock had declined over 27% year-to-date.